Consolidated Statement of Stockholders' Equity (unaudited) (USD $)	Total	Common stock issued @ $5.86	Common stock issued @ $18.95	Preferred stock issued at $1,000 per share	Common Stock Issued to Galloway	Issued To Novartis At Seven Dollar And Fifty Three Cents Per Share	Preferred Stock	Preferred Stock Preferred stock issued at $1,000 per share	Common Stock	Common Stock Common stock issued @ $5.86	Common Stock Common stock issued @ $18.95	Common Stock Common Stock Issued to Galloway	Common Stock Issued To Novartis At Seven Dollar And Fifty Three Cents Per Share	Additional Paid-in Capital	Additional Paid-in Capital Common stock issued @ $5.86	Additional Paid-in Capital Common stock issued @ $18.95	Additional Paid-in Capital Preferred stock issued at $1,000 per share	Additional Paid-in Capital Common Stock Issued to Galloway	Additional Paid-in Capital Issued To Novartis At Seven Dollar And Fifty Three Cents Per Share	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit during Development Stage	Noncontrolling Interest
Beginning Balance Amount at Sep. 30, 2013	$ 25,734,789						$ 10		$ 124,859					$ 193,514,766							$ (166,140,969)	$ (1,763,877)
Beginning Balance Shares at Sep. 30, 2013							9,900		32,489,444
Exercise of warrants, Amount	10,148,044								2,911					10,145,133
Exercise of warrants									2,911,919
Stock options exercised, Amount	2,730,000								455					2,729,545
Stock options exercised	454,863								454,863
Stock-based compensation	5,696,173													5,696,173
Stock issuances		14,060,112	112,581,559	46,000,000	500,000			46		3,072	6,325	132			14,057,040	112,575,234	45,999,954	499,868
Stock issuances, Shares								46,000		3,071,672	6,325,000	131,579
Settlements related to derivative liability	5,956,079													5,956,079
Preferred stock converted to common stock, Amount							(38)		9,272					(9,234)
Preferred stock converted to common stock, Shares							(37,600)		9,272,459
Deconsolidation of Calando Pharmaceuticals, Inc.	1,303,911																					1,303,911
Net loss	(58,725,412)																				(58,630,190)	(95,222)
Ending Balance Amount at Sep. 30, 2014	165,985,255						18		147,026					391,164,558							(224,771,159)	(555,188)
Ending Balance Shares at Sep. 30, 2014							18,300		54,656,936
Exercise of warrants, Amount	270,625								54					270,571
Exercise of warrants									53,578
Stock options exercised, Amount	43,126								18					43,108
Stock options exercised	17,500								17,500
Stock-based compensation	4,219,935													4,219,935
Exercise of exchange rights, Amount	3,072								5					3,067
Exercise of exchange rights, Shares									5,250
Stock issuances						25,000,000							3,321						24,996,679
Stock issuances, Shares													3,321,383
Preferred stock converted to common stock, Amount							(2)		1,316					(1,314)
Preferred stock converted to common stock, Shares							(2,648)		1,316,215
Common stock-RSU vesting, Amount									65					(65)
Common stock-RSU vesting, Shares									65,000
Net loss	(51,261,694)																				(51,261,694)
Foreign Currency Translation Adjustments	(63,965)																			(63,965)
Ending Balance Amount at Mar. 31, 2015	$ 144,196,354						$ 16		$ 151,805					$ 420,696,539						$ (63,965)	$ (276,032,853)	$ (555,188)
Ending Balance Shares at Mar. 31, 2015							15,652		59,435,862